Rib-X Pharmaceuticals, Inc. announced today that Mary Szela has been appointed to its Board of Directors as its Chair. Ms. Szela brings her 25-year career as an accomplished pharmaceutical executive to this leadership role.
"Mary Szela brings a wealth of talent and expertise to our team and is an outstanding choice to lead our Board of Directors,” said Mark Leuchtenberger, Chief Executive Officer of Rib-X. “Her broad commercial leadership experience will be particularly valuable as we continue to advance development of an urgently needed new antibiotic treatment option to patients and begin to consider options for launching the product. We look forward to working closely with Ms. Szela as we enter this exciting phase as a company and move ahead with our plans to initiate the Phase 3 program for delafloxacin for the treatment of acute bacterial skin and skin structure infections.”
With more than two decades in senior roles at Abbott Laboratories, Ms. Szela most recently served as Senior Vice President, Global Strategic Marketing and Services of the Pharmaceutical Products Group. Previously, she served as Senior Vice President of U.S. Pharmaceuticals, an $8 billion business. For over seven years, she directed the development, launch and growth of eight new pharmaceutical products, including leadership of Abbott's flagship product, Humira.
Prior to 2001, Ms. Szela held a series of senior positions in Abbott's hospital products division where she was responsible for the peri-operative, intensive care and pain management pharmaceutical business, the global One-2-One outsourcing business, the critical care device business and the vascular medicine pharmaceutical business.
Rib-X Pharmaceuticals, Inc. is a biopharmaceutical company developing new antibiotics to provide superior coverage, safety and convenience for the treatment of serious and life-threatening infections. The Company's proprietary drug discovery platform provides an atomic-level, three-dimensional understanding of interactions between drug candidates and their bacterial targets and enables design of antibiotics with enhanced characteristics. Rib-X has two antibiotic candidates in clinical development. Delafloxacin is an enhanced spectrum IV/oral antibiotic intended for use as first-line monotherapy primarily in hospitals and recently completed a Phase 2b clinical trial for the treatment of acute bacterial skin and skin structure infections. Radezolid is a next-generation IV/oral oxazolidinone designed to be a potent antibiotic with a safety profile permitting long-term treatment of resistant infections. The Company's pipeline also includes its preclinical RX-04 program, partnered with Sanofi, S.A., and other discovery stage anti-infective programs. For more information, please visit www.rib-x.com.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.